Browse All

Current Filters

CLEAR FILTER x

TITLE

What Features Are Most Important for the Diagnosis of Stiff Person Syndrome?

Author:Roy, Shuvro   Wang, Yujie   Huang, Yishang   Hu, Chen   Fitzgerald, Kathryn   Newsome, Scott   

Session Name:S18: Paraneoplastic Neurological Disorders, irAE, Stiff Person, IGLON5  

Topic:Autoimmune Neurology  

Program Number:S18.006  

Author Institution:University of Washington, Seattle, WA  Johns Hopkins University, Baltimore, MD  University of Pittsburgh, Pittsburgh, PA  Johns Hopkins Hospital, Baltimore, MD  

The Burden of “Invisible” (Non-Physical) Symptoms in Stiff Person Spectrum Disorders: A Cohort Survey Study

Author:Wang, Yujie   Huang, Yishang   Chen, Herbert   Newsome, Scott   

Session Name:P2: Autoimmune Neurology: Stiff Person Syndrome  

Topic:Autoimmune Neurology  

Program Number:P2.004  

Author Institution:University of Washington, Seattle, WA  Johns Hopkins University, Houston, TX  Johns Hopkins University, Baltimore, MD  

Video Head Impulse Test Characteristics of Anti-Glutamic Acid Decarboxylase (GAD)–Associated Neurologic Disorders

Author:Salazar Camelo, Ruth Andrea   Beauchamp, Norman   Wang, Yujie   Green, Kemar   Newsome, Scott   

Session Name:P2: Autoimmune Neurology: Stiff Person Syndrome  

Topic:Autoimmune Neurology  

Program Number:P2.009  

Author Institution:Johns Hopkins School of Medicine, Baltimore, MD  UW Northwest, Seattle, WA  

Investigating Cerebellar Atrophy by MRI as a Biomarker in Stiff Person Syndrome Spectrum Disorder and Anti-GAD65-associated Cerebellar Ataxia

Author:Krett, Jonathan   Riveros, Daniela   Chen, Herbert   Afshar, Hanyeh   Lin, Doris   Newsome, Scott   

Session Name:P2: Autoimmune Neurology: Stiff Person Syndrome  

Topic:Autoimmune Neurology  

Program Number:P2.010  

Author Institution:Johns Hopkins University School of Medicine, Baltimore, MD  

Ocrelizumab Subcutaneous Administration: Further Characterization of the Benefit–Risk Profile from the OCARINA II Study and Patient Preferences

Author:Newsome, Scott   Goldstick, Lawrence   Selmaj, Krzysztof   Krzystanek, Ewa   Zecevic, Dusanka   Figueiredo, Catarina   Clinch, Susanne   Giacobino, Caroline   Azmi, Jay   Centonze, Diego   

Session Name:P8: Multiple Sclerosis: Disease-modifying Therapies: Real-world Evidence and Adverse Events 2  

Topic:Multiple Sclerosis  

Program Number:P8.003  

Author Institution:Johns Hopkins University School of Medicine, Baltimore, MD, USA, Baltimore, MD  Department of Neurology and Rehabilitation Waddell Center for Multiple Sclerosis, University of Cincinnati, College of Medicine, Cincinnati, OH, USA, Cincinnati, OH  Centrum Neurologii, Lódz, Poland, Lódz, Poland  Department of Neurology, School of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland, Katowice, Poland  F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland  Roche Products Ltd, Welwyn Garden City, UK, Welwyn Garden City, United Kingdom  Unit of Neurology, IRCCS Neuromed, Pozzilli (IS), Italy, Rome, Italy